Across TCGA pan-cancer cohorts, C19orf44 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of C19orf44’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where C19orf44 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C19orf44 is over-expressed in tumor.
CCRCC are the cancer types where C19orf44 tumor–normal differential expression is most reproducible.